Article

New keratitis therapies show promise

Author(s):

Though fluoroquinolones remain mainstays for treating infectious keratitis, new medical therapies are emerging, said Eduardo C. Alfonso, MD.

 

New Orleans-Though fluoroquinolones remain mainstays for treating infectious keratitis, new medical therapies are emerging, said Eduardo C. Alfonso, MD.

“For bacterial keratitis, fluoroquinolones will continue to be developed into antibiotics that we will use with fortifications, in increasing concentrations of other antibiotics,” said Dr. Alfonso, professor and chairman, Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami.

Fortifications expand the toxicity of the floroquinolones, which, he said, is the most powerful group of antibiotics developed in medicine.

“For the eye, they have been wonderful, especially in regard to the fourth-generation fluoroquinolones in treating bacterial keratitis,” he said.

These include moxifloxacin, gatifloxacin, and besifloxacin.

Moxifloxacin, he said, has the best cure rate, and is better against Gram positives, whereas gatifloxacin is better against the Gram negatives. Besifloxacin is the newest, with no systemic use, and is more active than other fluoroquinolones versus resistant organisms.

Although still rare compared with bacterial keratitis, fungal keratitis cases cannot be overlooked, he said.

In the realm of fungal keratitis and Acanthamoeba keratitis, Dr. Alfonso said he believes molecular diagnosis will target therapy more precisely, as crosslinking holds great promise.

For fungal keratitis, several antifungal agents are available: commercially prepared natamycin, extemporaneously prepared voriconazole, amphotericin, fluconazole, itraconazole, caspofungin, and posaconazole.

A future treatment being developed is mycotoxin inhibition, Dr. Alfonso added. 

 

For more articles in this issue of Ophthalmology Times Conference Brief click here.

 

 

To receive weekly clinical news and updates in ophthalmology, subscribe to the Ophthalmology Times eReport.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Gregory Moloney, FRANZO, FRCSC, on rotational stability
Sheng Lim, MD, FRCOphth, discusses the CONCEPT study, which compared standalone cataract surgery to cataract surgery with ECP, at the 2025 ASCRS Annual Meeting.
© 2025 MJH Life Sciences

All rights reserved.